BRPI0909044A2 - anticorpo, sequência de ácidos nucleicos, vetor, composição farmacêutica, kit de partes, e, uso de um anticorpo, uma sequência de ácidos nucléicos, um vetor, uma composição farmacêutica ou um kit de partes - Google Patents

anticorpo, sequência de ácidos nucleicos, vetor, composição farmacêutica, kit de partes, e, uso de um anticorpo, uma sequência de ácidos nucléicos, um vetor, uma composição farmacêutica ou um kit de partes

Info

Publication number
BRPI0909044A2
BRPI0909044A2 BRPI0909044A BRPI0909044A BRPI0909044A2 BR PI0909044 A2 BRPI0909044 A2 BR PI0909044A2 BR PI0909044 A BRPI0909044 A BR PI0909044A BR PI0909044 A BRPI0909044 A BR PI0909044A BR PI0909044 A2 BRPI0909044 A2 BR PI0909044A2
Authority
BR
Brazil
Prior art keywords
antibody
vector
nucleic acid
acid sequence
pharmaceutical composition
Prior art date
Application number
BRPI0909044A
Other languages
English (en)
Inventor
Grellier Benoît
Thioudellet Christine
Haegel Hélène
Geist Michel
Original Assignee
Transgène S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgène S A filed Critical Transgène S A
Publication of BRPI0909044A2 publication Critical patent/BRPI0909044A2/pt
Publication of BRPI0909044B1 publication Critical patent/BRPI0909044B1/pt
Publication of BRPI0909044B8 publication Critical patent/BRPI0909044B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0909044A 2008-03-14 2009-03-11 anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos BRPI0909044B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08360005.6 2008-03-14
EP08360005 2008-03-14
US4388408P 2008-04-10 2008-04-10
US61/043884 2008-04-10
PCT/EP2009/001733 WO2009112245A1 (en) 2008-03-14 2009-03-11 Antibody against the csf-1 r

Publications (3)

Publication Number Publication Date
BRPI0909044A2 true BRPI0909044A2 (pt) 2017-05-30
BRPI0909044B1 BRPI0909044B1 (pt) 2020-12-29
BRPI0909044B8 BRPI0909044B8 (pt) 2021-05-25

Family

ID=40897505

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909044A BRPI0909044B8 (pt) 2008-03-14 2009-03-11 anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos

Country Status (18)

Country Link
US (2) US8604170B2 (pt)
EP (1) EP2262836B1 (pt)
JP (2) JP5805393B2 (pt)
KR (1) KR101633520B1 (pt)
CN (2) CN101970496B (pt)
AU (2) AU2009224955B2 (pt)
BR (1) BRPI0909044B8 (pt)
CA (1) CA2718499C (pt)
DK (1) DK2262836T3 (pt)
ES (1) ES2567298T3 (pt)
HK (1) HK1174644A1 (pt)
HU (1) HUE028756T2 (pt)
IL (1) IL208045A (pt)
MX (1) MX2010009894A (pt)
NZ (1) NZ587830A (pt)
RU (1) RU2547586C2 (pt)
WO (1) WO2009112245A1 (pt)
ZA (1) ZA201006497B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
ES2567298T3 (es) 2008-03-14 2016-04-21 Transgene Sa Anticuerpo contra el CSF-1R
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
RS58693B1 (sr) 2009-12-10 2019-06-28 Hoffmann La Roche Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
KR101656548B1 (ko) * 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
TWI713942B (zh) * 2010-05-04 2020-12-21 美商戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
DK2734547T3 (en) * 2011-07-18 2017-04-03 Univ Melbourne USE OF C-FMS ANTIBODIES
SG11201401639QA (en) * 2011-10-21 2014-05-29 Transgene Sa Modulation of macrophage activation
RU2658603C2 (ru) * 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
RU2014136332A (ru) * 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA2871445C (en) * 2012-05-11 2020-07-07 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AU2015264860B2 (en) * 2012-05-11 2017-03-02 Five Prime Therapeutics, Inc. Method of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP2938635A1 (en) * 2012-11-09 2015-11-04 Transgene SA Modulation of monocytes, or precursors thereof, differentiation
MX2015007575A (es) 2012-12-13 2016-03-15 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EP3096788B1 (en) * 2014-01-24 2019-07-31 Church, William, R. Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
AU2015280362B2 (en) 2014-06-23 2021-03-04 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
EP3835323A1 (en) 2014-10-29 2021-06-16 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN107427566B (zh) 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
EP3283527B1 (en) 2015-04-13 2021-01-13 Five Prime Therapeutics, Inc. Combination therapy for cancer
US10722517B2 (en) 2015-05-08 2020-07-28 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
JP6851322B2 (ja) * 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
BR112018076029A2 (pt) 2016-06-16 2019-03-26 Farmhannong Co., Ltd. métodos e composições para conferir e/ou melhorar tolerância a herbicida com o uso de protoporfirinogênio oxidase ou variante do mesmo
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
EP3486254A4 (en) * 2016-07-05 2019-12-18 Ibentrus, Inc. COMPOSITION FOR THE TREATMENT OF CANCER FOR INHIBITING TUMOR ANGIOGENESIS, CONTAINING A VEGF DEEP-BLOCKING AGENT, AND METHOD FOR PREPARING THE SAME
EP3504239A1 (en) 2016-08-25 2019-07-03 H. Hoffnabb-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
US20200031944A1 (en) 2017-03-31 2020-01-30 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
JP2020520943A (ja) 2017-05-19 2020-07-16 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法
BR112019025792A2 (pt) * 2017-06-07 2020-07-07 Spark Therapeutics, Inc. agentes de aperfeiçoamento para transfecção de células melhoradas e/ou produção de vetor raav
MX2020002301A (es) 2017-09-13 2020-07-13 Five Prime Therapeutics Inc Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
GB201803226D0 (en) 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
TWI733274B (zh) * 2018-12-13 2021-07-11 財團法人生物技術開發中心 抗人類csf-1r抗體及其用途
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2021058718A1 (en) 2019-09-26 2021-04-01 Roche Diagnostics Gmbh Anti-csf-1r antibody
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022141406A1 (zh) * 2020-12-31 2022-07-07 深圳先进技术研究院 一种能够提供治疗有效量的白介素10的试剂及其抗肿瘤应用
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH0517367A (ja) * 1991-07-08 1993-01-26 Green Cross Corp:The 骨粗鬆症治療剤
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
CA2388298C (en) 1999-10-28 2013-05-14 Seyedhossein Aharinejad The use of csf-1 inhibitors
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2005525314A (ja) * 2002-01-03 2005-08-25 トランジェーヌ、ソシエテ、アノニム 抗腫瘍療法のために使用可能な組み合わせ物
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
ES2543833T3 (es) 2004-01-07 2015-08-24 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
ES2364147T3 (es) 2004-01-16 2011-08-25 Regeneron Pharmaceuticals, Inc. Polipéptidos de fusión capaces de activar receptores.
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp SPECIFIC ORGAN PROTEINS AND METHODS OF USE
DK2188313T3 (en) 2007-08-21 2017-12-11 Amgen Inc HUMAN C-FMS ANTI-BINDING PROTEINS
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
ES2567298T3 (es) * 2008-03-14 2016-04-21 Transgene Sa Anticuerpo contra el CSF-1R

Also Published As

Publication number Publication date
BRPI0909044B8 (pt) 2021-05-25
IL208045A (en) 2014-12-31
IL208045A0 (en) 2010-12-30
EP2262836B1 (en) 2016-03-09
CA2718499C (en) 2019-06-11
AU2009224955A1 (en) 2009-09-17
ZA201006497B (en) 2011-06-29
AU2010257416A1 (en) 2011-01-20
JP5805393B2 (ja) 2015-11-04
BRPI0909044B1 (pt) 2020-12-29
HUE028756T2 (en) 2017-01-30
CN102702358A (zh) 2012-10-03
JP2015096522A (ja) 2015-05-21
AU2009224955B2 (en) 2012-08-09
HK1174644A1 (zh) 2013-06-14
RU2010141584A (ru) 2012-04-20
WO2009112245A1 (en) 2009-09-17
ES2567298T3 (es) 2016-04-21
DK2262836T3 (da) 2016-04-04
CN101970496B (zh) 2014-04-16
WO2009112245A9 (en) 2009-11-05
US9221912B2 (en) 2015-12-29
US8604170B2 (en) 2013-12-10
RU2547586C2 (ru) 2015-04-10
US20140057972A1 (en) 2014-02-27
EP2262836A1 (en) 2010-12-22
NZ587830A (en) 2012-08-31
KR101633520B1 (ko) 2016-06-24
CN102702358B (zh) 2016-02-17
KR20100122923A (ko) 2010-11-23
CA2718499A1 (en) 2009-09-17
AU2009224955A2 (en) 2010-10-28
CN101970496A (zh) 2011-02-09
AU2010257416B2 (en) 2012-05-31
US20110081353A1 (en) 2011-04-07
JP2011512851A (ja) 2011-04-28
MX2010009894A (es) 2011-02-22

Similar Documents

Publication Publication Date Title
BRPI0909044A2 (pt) anticorpo, sequência de ácidos nucleicos, vetor, composição farmacêutica, kit de partes, e, uso de um anticorpo, uma sequência de ácidos nucléicos, um vetor, uma composição farmacêutica ou um kit de partes
BRPI1007005A2 (pt) anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BR112012022210A2 (pt) anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
BRPI0817265A2 (pt) Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
BR112014022708A2 (pt) Uso de uma proteína ligante de neurotrofina p75ntr, uso de uma molécula de ácido nucleico, uso de um vetor de expressão replicável, célula hospedeira, composição farmacêutica e kit
SMT201600222B (it) Formulazione di anticorpi
BRPI0924177A2 (pt) Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI1006134A2 (pt) anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0914691A2 (pt) composto imunoadjuvante, composição, uso de um composto imunoadjuvante, ácido nucléico, vetor recombinante, e, célula hospedeira
BRPI0919377A2 (pt) anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0915137A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BR112012006326A2 (pt) anticorpo biespecífico, composição farmacêutica, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira procariótica ou eucariótica e invenção
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
DK2300472T3 (da) Glucocorticoidmimetika, fremgangsmåder til disses fremstilling, farmaceutiske sammensætninger samt anvendelser deraf
BR112014016076A8 (pt) peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0915136A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BRPI0812575A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, sequência de nucleotídeos
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2713 DE 03-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.